Unfortunately, all NA-NSAIDS, including selective COX-2 inhibitors, are associated with significant side effects, which hinder their use as CRC chemopreventive agents apart from FAP patients due to their high risk of developing CRC [93,103]. Here, PTGS2 is linked to colorectal carcinoma.